Amgen's appeal lies in its ability to generate massive cash flow while aggressively pivoting its portfolio to offset upcoming biosimilar competition. The Bull Case
The market is hyper-focused on MariTide , Amgen’s monthly-dose obesity candidate, which could disrupt the current weekly-dose market dominated by Eli Lilly and Novo Nordisk. is amgen a good stock to buy
In 2025, revenue grew 10% to $36.8 billion , with non-GAAP earnings per share (EPS) rising to $21.84 . Amgen's appeal lies in its ability to generate
Recent moves, such as the $840 million deal for Dark Blue Therapeutics, bolster its oncology pipeline in areas like acute myeloid leukemia (AML). The Bear Case Amgen’s monthly-dose obesity candidate
The company recently declared a $2.52 per share quarterly dividend, offering an attractive yield of approximately 2.9-3% .